BetterLife Pharma Inc. (OTCMKTS:BETRF) Stock Short Interest Drops 44.5%

BetterLife Pharma Inc. (OTCMKTS:BETRF) was the recipient of a significant decrease in short interest during the month of September. As of September 30th, there was short interest totaling 70,369 shares, a decrease of 44.5% from the September 15th total of 126,688 shares. Based on an average daily volume of 248,857 shares, the short-interest ratio is presently 0.3 days. Approximately 0.1% of the company’s shares are short sold.

BetterLife Pharma Stock Down 2.0%

OTCMKTS:BETRF opened at $0.16 on Friday. The company has a market cap of $27.08 million, a P/E ratio of -15.92 and a beta of 0.21. The firm’s 50 day moving average is $0.22 and its two-hundred day moving average is $0.13. BetterLife Pharma has a fifty-two week low of $0.03 and a fifty-two week high of $0.33.

BetterLife Pharma (OTCMKTS:BETRF) last announced its quarterly earnings data on Tuesday, September 29th. The company reported ($0.01) earnings per share (EPS) for the quarter.

About BetterLife Pharma

BetterLife Pharma Inc is a Canadian biotechnology company focused on developing innovative therapies for mental health and neurological disorders. The company’s research platform is based primarily on psychedelic-derived compounds designed to provide therapeutic benefits while reducing or eliminating unwanted hallucinogenic effects.

Its lead development program centers on BETR-001, a proprietary formulation of 2-bromo-LSD, which BetterLife is evaluating as a potential treatment for depression and related mental health conditions.